XFOR vs. NTGN, CDTX, AGTC, VALN, ITOS, TSHA, EXAI, KYTX, ADPT, and LXEO
Should you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include Neon Therapeutics (NTGN), Cidara Therapeutics (CDTX), Applied Genetic Technologies (AGTC), Valneva (VALN), iTeos Therapeutics (ITOS), Taysha Gene Therapies (TSHA), Exscientia (EXAI), Kyverna Therapeutics (KYTX), Adaptive Biotechnologies (ADPT), and Lexeo Therapeutics (LXEO). These companies are all part of the "medical" sector.
X4 Pharmaceuticals (NASDAQ:XFOR) and Neon Therapeutics (NASDAQ:NTGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, community ranking, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.
X4 Pharmaceuticals has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Neon Therapeutics has a beta of -0.81, meaning that its stock price is 181% less volatile than the S&P 500.
Neon Therapeutics received 97 more outperform votes than X4 Pharmaceuticals when rated by MarketBeat users. Likewise, 67.87% of users gave Neon Therapeutics an outperform vote while only 66.06% of users gave X4 Pharmaceuticals an outperform vote.
X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Neon Therapeutics, indicating that it is currently the more affordable of the two stocks.
X4 Pharmaceuticals currently has a consensus price target of $3.67, suggesting a potential upside of 263.04%. Given X4 Pharmaceuticals' higher possible upside, equities analysts clearly believe X4 Pharmaceuticals is more favorable than Neon Therapeutics.
In the previous week, X4 Pharmaceuticals had 5 more articles in the media than Neon Therapeutics. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 0 mentions for Neon Therapeutics. X4 Pharmaceuticals' average media sentiment score of 0.35 beat Neon Therapeutics' score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.
72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.7% of Neon Therapeutics shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 38.9% of Neon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Neon Therapeutics' return on equity of -199.09% beat X4 Pharmaceuticals' return on equity.
Summary
X4 Pharmaceuticals beats Neon Therapeutics on 8 of the 14 factors compared between the two stocks.
Get X4 Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
X4 Pharmaceuticals Competitors List
Related Companies and Tools
